The predictive significance of CD20 expression in B-cell lymphomas

<p>Abstract</p> <p>Background</p> <p>In our recent study, we determined the cut-off value of CD20 expression at the level of 25 000 molecules of equivalent soluble fluorochrome (MESF) to be the predictor of response to rituximab containing treatment in patients with B-cell lymphomas. In 17.5% of patients, who had the level of CD20 expression below the cut-off value, the response to rituximab containing treatment was significantly worse than in the rest of the patients with the level of CD20 expression above the cut-off value. The proportion of patients with low CD20 expression who might not benefit from rituximab containing treatment was not necessarily representative. Therefore the aim of this study was to quantify the CD20 expression in a larger series of patients with B-cell lymphomas which might allow us to determine more reliably the proportion of patients with the CD20 expression below the cut-off.</p> <p>Methods</p> <p>Cytological samples of 64 diffuse large B-cell lymphomas (DLBCL), 56 follicular lymphomas (FL), 31 chronic lymphocytic leukemias (CLL), 34 mantle cell lymphomas (MCL), 18 marginal zone lymphomas (MZL) and 15 B-cell lymphomas unclassified were analyzed for CD20 expression by quantitative four-color flow cytometric measurements using FACSCalibur flow cytometer (BD Biosciences).</p> <p>Results</p> <p>The range of CD20 expression in different B-cell lymphomas was very broad, varying from 2 737 to 115 623 MESF in CLL and 3 549 to 679 577 MESF in DLBCL. However, when we compared the CD20 expression in the groups of patients with DLBCL, FL, MCL, MZL, CLL and B-cell lymphomas unclassified, it was found to be significantly lower (p = 0.002) only in CLL but did not significantly differ in other lymphoma types (p = NS). Fifty-three out of 218 (24.3%) patients with B-cell lymphomas had the CD20 expression below the cut-off value.</p> <p>Conclusions</p> <p>The CD20 expression in CLL is significantly lower than in most histological types of mature B-cell lymphomas in which it appears to be comparable. Approximately 25% of B-cell lymphoma patients have the CD20 expression below the cut-off value showing that the low CD20 expression might be more common than presumed from our previous study.</p

Electrosynthesis of Co/PPy nanocomposites for ORR electrocatalysis: A study based on quasi-in situ X-ray absorption, fluorescence and in situ Raman spectroscopy

Cobalt/polypyrrole ORR electrocatalysts has been electrochemically synthesized by a potentiostatic anodic/cathodic pulse-plating procedure. The deposition electrochemistry has been studied by cyclic voltammetry and in-situ Micro Raman Spectroscopy complemented with scanning X-ray microscopy and micro-spot X-ray absorption spectroscopy (mu-XAS). Linear sweep voltammetry (LSV) under oxygen reduction has been used to assess the electrocatalytic effect of as-electrodeposited Co/PPy. The obtained results have provided new information about the concomitant electropolymerisation and metal incorporation processes occurring under different pulsed co-electrodeposition conditions, important for optimising the electrosynthesis procedure. The colocation of O and Co, evidenced by the O and Co XRF maps indicates that the Co in the formed composite is in oxidized state and for composites formed at low currents using shorter Co pulses coexistence of both CoO and Co3O4 is evidenced by the Co L-3 XAS spectra. Bimodal Co distribution as micro-grains on a background of nano-grains and co-nulcleation of PPy and Co is evidenced by correlation of Co and N XRF maps